New therapeutic strategies for hepatitis C

被引：126

作者：

Di Bisceglie, AM

McHutchinson, J

Rice, CM

机构：

[1] St Louis Univ, Sch Med, Dept Internal Med, Div Gastroenterol & Hepatol, St Louis, MO 63110 USA

[2] Scripps Res Inst, La Jolla, CA USA

[3] Rockefeller Univ, New York, NY 10021 USA

来源：

HEPATOLOGY | 2002年 / 35卷 / 01期

关键词：

D O I：

10.1053/jhep.2002.30531

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

Viral hepatitis is the single most important cause of liver disease in the United States and worldwide. With this in mind, the AASLD has launched an annual single topic conference devoted exclusively to viral hepatitis with the intention of bringing together researchers in viral hepatitis to foster progress in this important area. The first of these conferences, held June 15-16, 2001 in Chicago, IL, focused on new, evolving, and future approaches to therapy of hepatitis C.

引用

收藏

页码：224 / 231

页数：8

相关论文

共 41 条

[1] Protective immune response to hepatitis C virus in chimpanzees rechallenged following clearance of primary infection [J].

Bassett, SE ;

Guerra, B ;

Brasky, K ;

Miskovsky, E ;

Houghton, M ;

Klimpel, GR ;

Lanford, RE .

HEPATOLOGY, 2001, 33 (06) :1479-1487

[2] Efficient initiation of HCV RNA replication in cell culture [J].

Blight, KJ ;

Kolykhalov, AA ;

Rice, CM .

SCIENCE, 2000, 290 (5498) :1972-1974

[3] Toward a surrogate model for hepatitis C virus: An infectious molecular clone of the GB virus-B hepatitis agent [J].

Bukh, J ;

Apgar, CL ;

Yanagi, M .

VIROLOGY, 1999, 262 (02) :470-478

[4] RNA virus error catastrophe: Direct molecular test by using ribavirin [J].

Crotty, S ;

Cameron, CE ;

Andino, R .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2001, 98 (12) :6895-6900

[5] Natural history of hepatitis C: Its impact on clinical management [J].

Di Bisceglie, AM .

HEPATOLOGY, 2000, 31 (04) :1014-1018

[6] RIBAVIRIN AS THERAPY FOR CHRONIC HEPATITIS-C - A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL [J].

DIBISCEGLIE, AM ;

CONJEEVARAM, HS ;

FRIED, MW ;

SALLIE, R ;

PARK, Y ;

YURDAYDIN, C ;

SWAIN, M ;

KLEINER, DE ;

MAHANEY, K ;

HOOFNAGLE, JH ;

WRIGHT, D .

ANNALS OF INTERNAL MEDICINE, 1995, 123 (12) :897-&

[7] The outcome of acute hepatitis C predicted by the evolution of the viral quasispecies [J].

Farci, P ;

Shimoda, A ;

Coiana, A ;

Diaz, G ;

Peddis, G ;

Melpolder, JC ;

Strazzera, A ;

Chien, DY ;

Munoz, SJ ;

Balestrieri, A ;

Purcell, RH ;

Alter, HJ .

SCIENCE, 2000, 288 (5464) :339-344

[8] Hepatitis C virus lacking the hypervariable region 1 of the second envelope protein is infectious and causes acute resolving or persistent infection in chimpanzees [J].

Forns, X ;

Thimme, R ;

Govindarajan, S ;

Emerson, SU ;

Purcell, RH ;

Chisari, FV ;

Bukh, J .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2000, 97 (24) :13318-13323

[9] Pegylated (40 kDa) interferon alfa-2a (PEGASYS®) in combination with ribavirin:: Efficacy and safety results from a phase III, randomized, actively-controlled, multicenter study [J].

Fried, MW ;

Shiffman, ML ;

Reddy, RK ;

Smith, C ;

Marino, G ;

Goncales, F ;

Haeussinger, D ;

Diago, M ;

Carosi, G ;

Zarski, JP ;

Hoffman, J ;

Yu, J .

GASTROENTEROLOGY, 2001, 120 (05) :A55-A55

[10] Pegylated interferon-α2b:: Pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data [J].

Glue, P ;

Fang, JWS ;

Rouzier-Panis, R ;

Raffanel, C ;

Sabo, R ;

Gupta, SK ;

Salfi, M ;

Jacobs, S .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 2000, 68 (05) :556-567

← 1 2 3 4 5 →